Subjects -> MEDICAL SCIENCES (Total: 8695 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (220 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (339 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (234 journals)
    - DENTISTRY (294 journals)
    - DERMATOLOGY AND VENEREOLOGY (164 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (124 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (42 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (190 journals)
    - GERONTOLOGY AND GERIATRICS (137 journals)
    - HEMATOLOGY (157 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (179 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (98 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2418 journals)
    - NURSES AND NURSING (371 journals)
    - OBSTETRICS AND GYNECOLOGY (209 journals)
    - ONCOLOGY (385 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (140 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (171 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (275 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (159 journals)
    - PSYCHIATRY AND NEUROLOGY (835 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (192 journals)
    - RESPIRATORY DISEASES (105 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (82 journals)
    - SURGERY (405 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (156 journals)

UROLOGY, NEPHROLOGY AND ANDROLOGY (156 journals)                     

Showing 1 - 156 of 156 Journals sorted alphabetically
Acta Urológica Portuguesa     Open Access   (Followers: 1)
Actas Urológicas Españolas     Full-text available via subscription   (Followers: 3)
Actas Urológicas Españolas (English Edition)     Full-text available via subscription   (Followers: 1)
Advances in Chronic Kidney Disease     Full-text available via subscription   (Followers: 11)
Advances in Urology     Open Access   (Followers: 13)
African Journal of Nephrology     Open Access  
African Journal of Urology     Open Access   (Followers: 7)
AJP Renal Physiology     Hybrid Journal   (Followers: 8)
Aktuelle Urologie     Hybrid Journal   (Followers: 4)
American Journal of Kidney Diseases     Hybrid Journal   (Followers: 43)
American Journal of Men's Health     Open Access   (Followers: 9)
American Journal of Nephrology     Full-text available via subscription   (Followers: 37)
Andrologia     Hybrid Journal   (Followers: 2)
Andrology     Hybrid Journal   (Followers: 4)
Andrology & Gynecology : Current Research     Hybrid Journal   (Followers: 4)
Andrology and Genital Surgery     Open Access   (Followers: 7)
Andrology-Open Access     Open Access  
Annales d'Urologie     Full-text available via subscription  
Arab Journal of Nephrology and Transplantation     Open Access   (Followers: 1)
Arab Journal of Urology     Open Access   (Followers: 7)
Archives of Clinical Nephrology     Open Access   (Followers: 2)
Archivio Italiano di Urologia e Andrologia     Open Access   (Followers: 1)
Archivos Españoles de Urología     Open Access  
Asian Journal of Andrology     Open Access   (Followers: 1)
Asian Journal of Urology     Open Access   (Followers: 3)
Bangladesh Journal of Urology     Open Access   (Followers: 5)
BANTAO Journal     Open Access  
Basic and Clinical Andrology     Open Access  
BJU International     Hybrid Journal   (Followers: 34)
BMC Nephrology     Open Access   (Followers: 10)
BMC Urology     Open Access   (Followers: 14)
Canadian Journal of Kidney Health and Disease     Open Access   (Followers: 7)
Canadian Urological Association Journal     Open Access   (Followers: 2)
Cancer Urology     Open Access   (Followers: 2)
Cardiorenal Medicine     Full-text available via subscription   (Followers: 1)
Case Reports in Nephrology     Open Access   (Followers: 5)
Case Reports in Nephrology and Dialysis     Open Access   (Followers: 9)
Case Reports in Urology     Open Access   (Followers: 12)
Clinical and Experimental Nephrology     Hybrid Journal   (Followers: 4)
Clinical Journal of the American Society of Nephrology     Full-text available via subscription   (Followers: 20)
Clinical Kidney Journal     Open Access   (Followers: 4)
Clinical Medicine Insights : Urology     Open Access   (Followers: 3)
Clinical Nephrology     Full-text available via subscription   (Followers: 8)
Clinical Nephrology and Urology Science     Open Access   (Followers: 6)
Clinical Queries: Nephrology     Hybrid Journal   (Followers: 1)
Cuadernos de Cirugía     Open Access   (Followers: 3)
Current Opinion in Nephrology & Hypertension     Hybrid Journal   (Followers: 10)
Current Opinion in Urology     Hybrid Journal   (Followers: 12)
Current Urology     Open Access   (Followers: 10)
Current Urology Reports     Hybrid Journal   (Followers: 5)
Der Nephrologe     Hybrid Journal  
Der Urologe     Hybrid Journal   (Followers: 1)
EMC - Urología     Full-text available via subscription  
Enfermería Nefrológica     Open Access   (Followers: 1)
European Urology     Full-text available via subscription   (Followers: 34)
European Urology Focus     Hybrid Journal   (Followers: 4)
European Urology Supplements     Full-text available via subscription   (Followers: 10)
Forum Nefrologiczne     Full-text available via subscription  
Geriatric Nephrology and Urology     Hybrid Journal   (Followers: 7)
Giornale di Clinica Nefrologica e Dialisi     Open Access  
Herald Urology     Open Access   (Followers: 2)
Hong Kong Journal of Nephrology     Open Access   (Followers: 3)
Human Andrology     Partially Free   (Followers: 2)
IJU Case Reports     Open Access  
Indian Journal of Nephrology     Open Access   (Followers: 2)
Indian Journal of Urology     Open Access   (Followers: 5)
International Brazilian Journal of Urology     Open Access   (Followers: 5)
International Journal of Nephrology     Open Access   (Followers: 2)
International Journal of Nephrology and Renovascular Disease     Open Access   (Followers: 2)
International Journal of Urology     Hybrid Journal   (Followers: 12)
International Urology and Nephrology     Hybrid Journal   (Followers: 7)
Jornal Brasileiro de Nefrologia     Open Access  
Journal für Urologie und Urogynäkologie/Österreich     Hybrid Journal  
Journal of Clinical Nephrology     Open Access   (Followers: 1)
Journal of Clinical Urology     Hybrid Journal   (Followers: 14)
Journal of Endoluminal Endourology     Open Access  
Journal of Endourology     Hybrid Journal   (Followers: 2)
Journal of Endourology Case Reports     Hybrid Journal  
Journal of Genital System & Disorders     Hybrid Journal   (Followers: 3)
Journal of Integrative Nephrology and Andrology     Open Access   (Followers: 2)
Journal of Kidney Cancer and VHL     Open Access  
Journal of Lower Genital Tract Disease     Hybrid Journal  
Journal of Nephrology     Hybrid Journal   (Followers: 4)
Journal of Nephrology Research     Open Access   (Followers: 3)
Journal of Pediatric Nephrology     Open Access   (Followers: 4)
Journal of Renal Care     Hybrid Journal   (Followers: 8)
Journal of Renal Nursing     Full-text available via subscription   (Followers: 12)
Journal of Renal Nutrition     Hybrid Journal   (Followers: 28)
Journal of Renal Nutrition and Metabolism     Open Access   (Followers: 1)
Journal of the American Society of Nephrology     Full-text available via subscription   (Followers: 29)
Journal of The Egyptian Society of Nephrology and Transplantation     Open Access  
Journal of Translational Neurosciences     Open Access  
Journal of Urology     Full-text available via subscription   (Followers: 45)
Journal of Urology & Nephrology     Open Access   (Followers: 2)
Kidney Disease and Transplantation     Open Access   (Followers: 4)
Kidney Diseases     Open Access   (Followers: 3)
Kidney International     Hybrid Journal   (Followers: 46)
Kidney International Reports     Open Access   (Followers: 3)
Kidney Medicine     Open Access  
Kidney Research Journal     Open Access   (Followers: 6)
Kidneys (Počki)     Open Access   (Followers: 1)
Nature Reviews Nephrology     Full-text available via subscription   (Followers: 21)
Nature Reviews Urology     Full-text available via subscription   (Followers: 12)
Nefrología (English Edition)     Open Access  
Nefrología (Madrid)     Open Access  
Nephro-Urology Monthly     Open Access   (Followers: 1)
Nephrology     Hybrid Journal   (Followers: 13)
Nephrology Dialysis Transplantation     Hybrid Journal   (Followers: 26)
Nephron     Hybrid Journal   (Followers: 4)
Nephron Clinical Practice     Full-text available via subscription   (Followers: 4)
Nephron Experimental Nephrology     Full-text available via subscription   (Followers: 4)
Nephron Extra     Open Access   (Followers: 1)
Nephron Physiology     Full-text available via subscription   (Followers: 4)
Neurourology and Urodynamics     Hybrid Journal   (Followers: 1)
OA Nephrology     Open Access   (Followers: 2)
Open Access Journal of Urology     Open Access   (Followers: 6)
Open Journal of Nephrology     Open Access   (Followers: 5)
Open Journal of Urology     Open Access   (Followers: 6)
Open Urology & Nephrology Journal     Open Access  
Pediatric Urology Case Reports     Open Access   (Followers: 7)
Portuguese Journal of Nephrology & Hypertension     Open Access   (Followers: 1)
Progrès en Urologie     Full-text available via subscription  
Progrès en Urologie - FMC     Full-text available via subscription  
Prostate Cancer and Prostatic Diseases     Hybrid Journal   (Followers: 6)
Renal Failure     Open Access   (Followers: 12)
Renal Replacement Therapy     Open Access   (Followers: 4)
Research and Reports in Urology     Open Access   (Followers: 4)
Revista de Nefrología, Diálisis y Trasplante     Open Access   (Followers: 1)
Revista Mexicana de Urología     Open Access   (Followers: 1)
Revista Urologia Colombiana     Open Access  
Saudi Journal of Kidney Diseases and Transplantation     Open Access   (Followers: 2)
Scandinavian Journal of Urology     Hybrid Journal   (Followers: 7)
Seminars in Nephrology     Hybrid Journal   (Followers: 11)
The Prostate     Hybrid Journal   (Followers: 8)
Therapeutic Advances in Urology     Open Access   (Followers: 4)
Trends in Urology & Men's Health     Partially Free   (Followers: 1)
Ukrainian Journal of Nephrology and Dialysis     Open Access   (Followers: 1)
Uro-News     Hybrid Journal   (Followers: 1)
Urolithiasis     Hybrid Journal   (Followers: 2)
Urologia Internationalis     Full-text available via subscription   (Followers: 2)
Urologia Journal     Hybrid Journal  
Urologic Clinics of North America     Full-text available via subscription   (Followers: 4)
Urologic Nursing     Full-text available via subscription   (Followers: 4)
Urologic Radiology     Hybrid Journal  
Urological Science     Open Access  
Urologicheskie Vedomosti     Open Access  
Urologie in der Praxis     Hybrid Journal  
Urologie Scan     Hybrid Journal  
Urology     Hybrid Journal   (Followers: 33)
Urology Annals     Open Access   (Followers: 4)
Urology Case Reports     Open Access   (Followers: 3)
Urology Practice     Full-text available via subscription   (Followers: 2)
Urology Times     Free   (Followers: 3)
Urology Video Journal     Open Access   (Followers: 1)
World Journal of Nephrology and Urology     Open Access   (Followers: 15)
World Journal of Urology     Hybrid Journal   (Followers: 11)

           

Similar Journals
Journal Cover
Nephrology Dialysis Transplantation
Journal Prestige (SJR): 2.142
Citation Impact (citeScore): 4
Number of Followers: 26  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0931-0509 - ISSN (Online) 1460-2385
Published by Oxford University Press Homepage  [413 journals]
  • Virtual reality: the dawn of a new ERA
    • Authors: Stevens K; Palladino G, Almiron J, et al.
      Pages: 1 - 4
      Abstract: Graphical Abstract
      PubDate: Fri, 16 Oct 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa255
      Issue No: Vol. 36, No. 1 (2020)
       
  • Every obstruction does not need a stent: an important lesson from the
           ISCHEMIA-CKD trial for kidney-transplant surgeons
    • Authors: Georgianos P; Agarwal R.
      Pages: 4 - 8
      Abstract: Revascularization either with percutaneous coronary intervention (PCI) or with coronary artery bypass grafting (CABG), as appropriate, is the guideline-based therapy for patients presenting with acute coronary syndromes [1]. In contrast, the optimal management of stableischaemic heart disease (ISHD) remains uncertain. Prior randomized trials among patients with stable ISHD have suggested no benefit of an invasive strategy over optimal medical treatment (OMT) [2, 3]. These trials have been criticized because a large proportion of participants had minimal symptom burden and low-to-moderate myocardial ischaemia, and therefore the rates of revascularization were low in the group assigned to interventional therapy [2, 3]. Furthermore, patients with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 or those on dialysis were either underrepresented or excluded from these trials (Table 1). Thus, the management of stable ISHD, particularly in patients with advanced chronic kidney disease (CKD), is based on low-quality evidence provided by small post hoc analyses of randomized trials [6] or on observational data [7].
      PubDate: Mon, 20 Jul 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa157
      Issue No: Vol. 36, No. 1 (2020)
       
  • COVID-19 and policy changes for kidney disease: the need for a
           ‘decade of the kidney’
    • Authors: Vanholder R; Lameire N.
      Pages: 8 - 11
      Abstract: In this issue of Nephrology Dialysis Transplantation, a timely analysis and call to action by the Council of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and the European Renal Association COVID-19 Database (ERACODA) working group [1] highlights the extremely high burden of coronavirus disease 2019 (COVID-19) infection in chronic kidney disease (CKD) patients, who, compared with patients suffering from other major disorders, are at the highest risk to develop severe COVID-19 and to die from it [2].
      PubDate: Tue, 29 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa339
      Issue No: Vol. 36, No. 1 (2020)
       
  • Rituximab in fibrillary glomerulonephritis: fumble or forward
           progress'
    • Authors: Wadhwani S; Jhaveri K.
      Pages: 11 - 13
      Abstract: While prospective, double-blind, randomized controlled trials continue to be regarded as the holy grail and hard endpoints such as progression to end-stage kidney disease (ESKD) or death are considered the gold standard, there has been increasing effort in the research arena to limit costs and patient burden. With support from federal agencies to help move kidney therapies down the pipeline, there has been a shift toward shorter follow-up time and more frequent use of surrogate endpoints such as proteinuria or a 40% decline in estimated glomerular filtration rate (eGFR). For most rare diseases, however, large-scale clinical trials may not be feasible and we must rely on less robust data or expert opinion to guide management. In addition to being uncommon, glomerular diseases pose additional challenges, given heterogeneity in disease presentation, delays in diagnosis and lack of predictable response to treatment. In this issue, Erickson et al. [1] tackle treatment of fibrillary glomerulonephritis (FGN), a rare, progressive, glomerular disease with no currently approved therapies.
      PubDate: Tue, 11 Aug 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa186
      Issue No: Vol. 36, No. 1 (2020)
       
  • Personalizing potassium management in patients on haemodialysis
    • Authors: Wouda R; Vogt L, Hoorn E.
      Pages: 13 - 18
      Abstract: The regulation of potassium homoeostasis changes dramatically in patients with kidney failure who are treated by haemodialysis. With the kidney largely out of the equation, haemodialysis patients rely on potassium removal during each dialysis session to prevent hyperkalaemia. In addition, the gut becomes an important accessory organ for potassium excretion [1]. Despite these adaptations, hyperkalaemia (defined as serum potassium >5.5 mmol/L) remains a common electrolyte disorder occurring in approximately 14% of haemodialysis patients [2]. Although seemingly counterintuitive, a minority of haemodialysis patients is hypokalaemic (serum potassium <3.5 mmol/L), and this is usually related to poor dietary intake [3]. The target serum potassium in haemodialysis is unknown, but one study suggests that a serum potassium between 4.6 and 5.3 mmol/L is associated with the greatest survival [3]. Of note, in patients with chronic kidney disease (CKD), this optimal serum potassium range seems to be lower (4.0–4.5 mmol/L) [4]. Furthermore , when analysing serum potassium in haemodialysis patients, it is important to factor in when it was measured (after the long or short interdialytic interval, time of day and seasonality), and to analyse serial measurements to exclude transient hyperkalemia [2, 5]. Nephrologists can manage potassium balance in haemodialysis patients in three ways, including (i) by modifying the dialysate potassium concentration, (ii) by prescribing potassium binders and (iii) by modifying dietary potassium intake (Figure 1). The reason to implement such interventions is usually driven by recurring predialysis hyperkalaemia and the related risk of cardiac arrhythmia [6]. Although the prevention of acute complications is important, another relevant question is how these interventions affect long-term outcomes in haemodialysis patients. Unfortunately, there is a scarcity of randomized controlled trials in this area. Therefore, instead, we need to rely on registries, which often provide useful insights into how real-world management influences long-term outcomes. A good example of such a registry is the French Renal Epidemiology and Information Network (REIN). In this issue, Mercadal et al. [7] use this registry to analyse the effect of prescription patterns of dialysate potassium and potassium binders on survival in over 25 000 patients who started haemodialysis in 2010–13 and were followed until the end of 2014. Using Cox proportional hazard models, the investigators show that dialysis centres that used two or three dialysate potassium concentrations had a lower mortality risk than centres that only used one formula. In addition, patients who used the potassium binder sodium or calcium polystyrene sulphonate in a dose of 4–8 or ≥8 g/day had a lower mortality risk than patients who did not use potassium binders. Conversely, patients who used potassium binders in a dose <4 g/day had a higher mortality risk. Oral potassium supplements, which were used in 6% of patients, were not associated with a survival benefit. What does this study teach us on potassium management in haemodialysis patients and what are the implications for clinical practice'
      PubDate: Thu, 22 Oct 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa213
      Issue No: Vol. 36, No. 1 (2020)
       
  • One concept does not fit all: the immune system in different forms of
           acute kidney injury
    • Authors: Anders H; Wilkens L, Schraml B, et al.
      Pages: 29 - 38
      Abstract: AbstractRenal and immune systems maintain body homoeostasis during physiological fluctuations and following tissue injury. The immune system plays a central role during acute kidney injury (AKI), adapting evolutional systems programmed for host defence and minimizing unnecessary collateral damage. Indeed, depending upon the disease context, the impact of the immune system upon the manifestations and consequences of AKI can be quite different. Here we provide an overview of the known and unknown involvement of the immune system within the wide range of different forms of AKI, to oppose oversimplification and to endorse deeper insights into the pathogenesis of the different diseases causing kidney injury. This approach may help to overcome some of the current hurdles in translational AKI research and the development of specific treatments for the different diseases, all presenting with an acute increase in serum creatinine or decline in urinary output. One concept does not fit all.
      PubDate: Sun, 26 Apr 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa056
      Issue No: Vol. 36, No. 1 (2020)
       
  • Cystatin C to predict renal disease and cardiovascular risk
    • Authors: Lees J; Mark P.
      Pages: 39 - 41
      Abstract: Graphical Abstract
      PubDate: Tue, 09 Jun 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa152
      Issue No: Vol. 36, No. 1 (2020)
       
  • European Consensus Statement on the diagnosis and management of
           osteoporosis in chronic kidney disease stages G4–G5D
    • Authors: Evenepoel P; Cunningham J, Ferrari S, et al.
      Pages: 42 - 59
      Abstract: AbstractControlling the excessive fracture burden in patients with chronic kidney disease (CKD) Stages G4–G5D remains an impressive challenge. The reasons are 2-fold. First, the pathophysiology of bone fragility in patients with CKD G4–G5D is complex and multifaceted, comprising a mixture of age-related (primary male/postmenopausal), drug-induced and CKD-related bone abnormalities. Second, our current armamentarium of osteoporosis medications has not been developed for, or adequately studied in patients with CKD G4–G5D, partly related to difficulties in diagnosing osteoporosis in this specific setting and fear of complications. Doubts about the optimal diagnostic and therapeutic approach fuel inertia in daily clinical practice. The scope of the present consensus paper is to review and update the assessment and diagnosis of osteoporosis in patients with CKD G4-G5D and to discuss the therapeutic interventions available and the manner in which these can be used to develop management strategies for the prevention of fragility fracture. As such, it aims to stimulate a cohesive approach to the management of osteoporosis in patients with CKD G4–G5D to replace current variations in care and treatment nihilism.
      PubDate: Sat, 24 Oct 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa192
      Issue No: Vol. 36, No. 1 (2020)
       
  • Differential role of nicotinamide adenine dinucleotide deficiency in acute
           and chronic kidney disease
    • Authors: Faivre A; Katsyuba E, Verissimo T, et al.
      Pages: 60 - 68
      Abstract: AbstractBackgroundNicotinamide adenine dinucleotide (NAD+) is a ubiquitous coenzyme involved in electron transport and a co-substrate for sirtuin function. NAD+ deficiency has been demonstrated in the context of acute kidney injury (AKI).MethodsWe studied the expression of key NAD+ biosynthesis enzymes in kidney biopsies from human allograft patients and patients with chronic kidney disease (CKD) at different stages. We used ischaemia–reperfusion injury (IRI) and cisplatin injection to model AKI, urinary tract obstruction [unilateral ureteral obstruction (UUO)] and tubulointerstitial fibrosis induced by proteinuria to investigate CKD in mice. We assessed the effect of nicotinamide riboside (NR) supplementation on AKI and CKD in animal models.ResultsRNA sequencing analysis of human kidney allograft biopsies during the reperfusion phase showed that the NAD+de novo synthesis is impaired in the immediate post-transplantation period, whereas the salvage pathway is stimulated. This decrease in de novo NAD+ synthesis was confirmed in two mouse models of IRI where NR supplementation prevented plasma urea and creatinine elevation and tubular injury. In human biopsies from CKD patients, the NAD+de novo synthesis pathway was impaired according to CKD stage, with better preservation of the salvage pathway. Similar alterations in gene expression were observed in mice with UUO or chronic proteinuric glomerular disease. NR supplementation did not prevent CKD progression, in contrast to its efficacy in AKI.ConclusionImpairment of NAD+ synthesis is a hallmark of AKI and CKD. NR supplementation is beneficial in ischaemic AKI but not in CKD models.
      PubDate: Sun, 25 Oct 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa124
      Issue No: Vol. 36, No. 1 (2020)
       
  • Evidence of an intestinal phosphate transporter alternative to type IIb
           sodium-dependent phosphate transporter in rats with chronic kidney
           disease
    • Authors: Ichida Y; Ohtomo S, Yamamoto T, et al.
      Pages: 68 - 75
      Abstract: AbstractBackgroundPhosphate is absorbed in the small intestine via passive flow and active transport.NaPi-IIb, a type II sodium-dependent phosphate transporter, is considered to mediate active phosphate transport in rodents. To study the regulation of intestinal phosphate transport in chronic kidney disease (CKD), we analyzed the expression levels of NaPi-IIb, pituitary-specific transcription factor 1 (PiT-1) and PiT-2 and the kinetics of intestinal phosphate transport using two CKD models.MethodsCKD was induced in rats via adenine orThy1 antibody injection. Phosphate uptake by intestinal brush border membrane vesicles (BBMV) and the messenger RNA (mRNA) expression of NaPi-IIb, PiT-1 and PiT-2 were analyzed. The protein expression level of NaPi-IIb was measured by mass spectrometry (e.g. liquid chromatography tandem mass spectrometry).ResultsIn normal rats, phosphate uptake into BBMV consisted of a single saturable component and its Michaelis constant (Km) was comparable to that of NaPi-IIb. The maximum velocity (Vmax) correlated with mRNA and protein levels of NaPi-IIb. In the CKD models, intestinal phosphate uptake consisted of two saturable components. The Vmax of the higher-affinity transport, which is thought to be responsible for NaPi-IIb, significantly decreased and the decrease correlated with reduced NaPi-IIb expression. The Km of the lower-affinity transport was comparable to that of PiT-1 and -2. PiT-1 mRNA expression was much higher than that of PiT-2, suggesting that PiT-1 was mostly responsible for phosphate transport.ConclusionsThis study suggests that the contribution of NaPi-IIb to intestinal phosphate absorption dramatically decreases in rats with CKD and that a low-affinity alternative to NaPi-IIb, in particular PiT-1, is upregulated in a compensatory manner in CKD.
      PubDate: Thu, 03 Sep 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa156
      Issue No: Vol. 36, No. 1 (2020)
       
  • Aberrant mucosal immunoreaction to tonsillar microbiota in immunoglobulin
           A nephropathy
    • Authors: Yamaguchi H; Goto S, Takahashi N, et al.
      Pages: 75 - 86
      Abstract: AbstractBackgroundImmunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide, characterized by mesangial polymeric IgA1 deposition. IgAN is believed to develop owing to aberrant mucosal immunoreaction against commensals in the tonsils. However, the exact interrelation between pathogenic IgA and mucosal microbiota in IgAN patients is unclear.MethodsBiopsy-proven IgAN or recurrent tonsillitis (RT) patients who had undergone tonsillectomy were enrolled. We used 16S ribosomal RNA gene amplicon sequencing with a flow cytometry-based bacterial cell sorting technique) and immunoglobulin repertoire sequencing of the IgA heavy chain to characterize IgA-coated bacteria of the tonsillar microbiota (IgA-SEQ) and their corresponding IgA repertoire. Furthermore, we fractionated patient serum using gel-filtration chromatography and performed flow cytometry-based analysis of IgA binding to bacteria cultured from incised tonsils.ResultsTonsillar proliferation-inducing ligand and B-cell activating factor levels were significantly higher in IgAN than in RT patients. IgA-SEQ for tonsillar microbiota revealed the preferential binding ability of IgA to Bacteroidetes in IgAN tonsils compared with those from RT patients. Expression of immunoglobulin heavy (IGH) constant alpha 1 with IGH variable 3–30 was significantly higher in IgAN than that in RT, and positively correlated with the IgA-coated enrichment score of Bacteroidetes. Serum polymeric IgA, comprising high levels of GdIgA1, exhibited considerable binding to Bacteroidetes strains cultured from the tonsils of IgAN patients.ConclusionsThese findings provide evidence that aberrant mucosal immune responses to tonsillar anaerobic microbiota, primarily consisting of members of the phylum Bacteroidetes, are involved in IgAN pathophysiology.
      PubDate: Sun, 25 Oct 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa223
      Issue No: Vol. 36, No. 1 (2020)
       
  • Chronic kidney disease is a key risk factor for severe COVID-19: a call to
           action by the ERA-EDTA
    • Pages: 87 - 94
      Abstract: AbstractDiabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients. The picture that arose differs significantly from initial reports. For example, hypertension is not an independent risk factor for COVID-19 death [adjusted hazard ratio (aHR) 0.89], but renal disease very much is. Dialysis (aHR 3.69), organ transplantation (aHR 3.53) and CKD (aHR 2.52 for patients with eGFR <30 mL/min/1.73 m2) represent three of the four comorbidities associated with the highest mortality risk from COVID-19. The risk associated with CKD Stages 4 and 5 is higher than the risk associated with diabetes mellitus (aHR range 1.31–1.95, depending upon glycaemic control) or chronic heart disease (aHR 1.17). In another recent publication, the Global Burden of Disease collaboration identified that worldwide, CKD is the most prevalent risk factor for severe COVID-19. Moreover, the distribution of risk factors for COVID-19 mortality appears to be different in patients with CKD when compared with the general population. The high prevalence of CKD in combination with the elevated risk of mortality from COVID-19 in CKD necessitates urgent action for this group of patients. This article defines essential action points (summarized in Box 1), among which is advocating the inclusion of CKD patients in clinical trials testing the efficacy of drugs and vaccines to prevent severe COVID-19.
      PubDate: Sat, 19 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa314
      Issue No: Vol. 36, No. 1 (2020)
       
  • Treatment of fibrillary glomerulonephritis with rituximab: a 12-month
           pilot study
    • Authors: Erickson S; Zand L, Nasr S, et al.
      Pages: 104 - 110
      Abstract: AbstractBackgroundFibrillary glomerulonephritis (FGN) is a rare type of glomerulonephritis with poor prognosis, with no known effective therapies available for treatment. The objective of the study was to evaluate the efficacy and safety of rituximab in treatment of patients with FGN and to investigate the effect of rituximab on DNAJB9 levels.MethodsThis was a pilot prospective clinical trial in which patients with idiopathic FGN were treated with two courses of rituximab (1 g each) 2 weeks apart at the beginning and then again at 6 months. Primary outcome was defined as preservation of kidney function at 12 months with stable or increased creatinine clearance. Secondary outcome was defined as achieving complete remission (CR) defined as proteinuria <300 mg/24 h or partial remission (PR) with proteinuria <3 g/24 h and at least 50% reduction in the proteinuria. DNAJB9 levels were also measured in the serum at baseline, 6 and 12 months.ResultsThe creatinine clearance did not change significantly during this time, from 47.7 mL/min/1.73 m2 at baseline to 43.7 mL/min/1.73 m2 during follow-up (P = 0.15). Proteinuria declined from 4.43 (1.6–5.53) g/24 h at baseline to 1.9 (0.46–5.26) g/24 h at 12 months but did not reach significance (P = 0.06). None of the patients reached CR, and 3 of the 11 achieved PR. There was no change in the DNAJB9 levels following treatment with rituximab. The most common adverse event was nasal congestion, fatigue and muscle cramps.ConclusionsTreatment of patients with two courses of rituximab over a span of 6 months was associated with stabilization of renal function but did not result in a significant change in proteinuria and with no change in the DNAJB9 levels.
      PubDate: Thu, 02 Jul 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa065
      Issue No: Vol. 36, No. 1 (2020)
       
  • Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus
           iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO
           randomized, open-label, comparative trial
    • Authors: Bhandari S; Kalra P, Berkowitz M, et al.
      Pages: 111 - 120
      Abstract: AbstractBackgroundThe optimal intravenous (IV) iron would allow safe correction of iron deficiency at a single infusion over a short time. The FERWON-NEPHRO trial evaluated the safety and efficacy of iron isomaltoside 1000/ferric derisomaltose (IIM) in patients with non-dialysis-dependent chronic kidney disease and iron deficiency anaemia.MethodsIn this randomized, open-label and multi-centre trial conducted in the USA, patients were randomized 2:1 to a single dose of 1000 mg IIM or iron sucrose (IS) administered as 200 mg IV injections up to five times within a 2-week period. The co-primary endpoints were serious or severe hypersensitivity reactions and change in haemoglobin (Hb) from baseline to Week 8. Secondary endpoints included incidence of composite cardiovascular adverse events (AEs).ResultsA total of 1538 patients were enrolled (mean estimated glomerular filtration rate 35.5 mL/min/1.73 m2). The co-primary safety objective was met based on no significant difference in the incidence of serious or severe hypersensitivity reactions in the IIM and IS groups [0.3% versus 0%; risk difference: 0.29% (95% confidence interval: –0.19; 0.77; P > 0.05)]. Incidence of composite cardiovascular AEs was significantly lower in the IIM versus IS group (4.1% versus 6.9%; P = 0.025). Compared with IS, IIM led to a more pronounced increase in Hb during the first 4 weeks (P ≤ 0.021), and change in Hb to Week 8 showed non-inferiority, confirming that the co-primary efficacy objective was met.ConclusionsCompared with multiple doses of IS, a single dose of IIM induced a non-inferior 8-week haematological response, comparably low rates of hypersensitivity reactions, and a significantly lower incidence of composite cardiovascular AEs.
      PubDate: Wed, 12 Feb 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa011
      Issue No: Vol. 36, No. 1 (2020)
       
  • Fibroblast growth factor 23 and new-onset chronic kidney disease in the
           general population: the Prevention of Renal and Vascular Endstage Disease
           (PREVEND) study
    • Authors: De Jong M; Eisenga M, van Ballegooijen A, et al.
      Pages: 121 - 128
      Abstract: AbstractBackgroundFibroblast growth factor 23 (FGF23), a phosphate-regulating hormone that increases early in the course of chronic kidney disease (CKD), is associated with disease progression in patients with established CKD. Here we aimed to investigate the association between plasma FGF23 and new-onset CKD in the general population.MethodsWe included 5253 individuals without CKD who participated in the Prevention of Renal and Vascular Endstage Disease study, a prospective, population-based cohort. Multi-variable Cox regression was used to study the association of plasma C-terminal FGF23 with new-onset CKD, defined as a combined endpoint of estimated glomerular filtration rate (eGFR) <60 mL/min/ 1.73 m2, urinary 24-h albumin excretion (UAE) >30 mg/24 h or both, or with all-cause mortality.ResultsThe median baseline FGF23 was 68 [interquartile range (IQR) 56–85] RU/mL, eGFR was 95 ± 13 mL/min/1.73 m2 and UAE was 7.8 (IQR 5.8–11.5)  mg/24 h. After follow-up of 7.5 (IQR 7.2–8.0)  years, 586 participants developed CKD and 214 participants died. A higher FGF23 level was associated with new-onset CKD, independent of risk factors for kidney disease and parameters of bone and mineral homoeostasis {fully adjusted hazard ratio (HR) 1.25 [95% confidence interval (CI) 1.10–1.44] per doubling of FGF23; P = 0.001}. In secondary analyses, FGF23 was independently associated with new-onset eGFR <60 mL/min/1.73 m2 [adjusted HR 1.28 (95% CI 1.00–1.62); P = 0.048] or with UAE >30 mg/24 h [adjusted HR 1.24 (95% CI 1.06–1.45); P = 0.01] individually. A higher FGF23 level was also associated with an increased risk of all-cause mortality [fully adjusted HR 1.30 (95% CI 1.03–1.63); P = 0.03].ConclusionsHigh FGF23 levels are associated with an increased risk of new-onset CKD and all-cause mortality in this prospective population-based cohort, independent of established CKD risk factors.
      PubDate: Tue, 03 Mar 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfz266
      Issue No: Vol. 36, No. 1 (2020)
       
  • Long-term safety and efficacy of sodium zirconium cyclosilicate for
           hyperkalaemia in patients with mild/moderate versus severe/end-stage
           chronic kidney disease: comparative results from an open-label, Phase 3
           study
    • Authors: Roger S; Lavin P, Lerma E, et al.
      Pages: 137 - 150
      Abstract: AbstractBackgroundSodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K+) binder for the treatment of adults with hyperkalaemia. This post hoc analysis of an open-label, single-arm trial (NCT02163499) compared SZC efficacy and safety >12 months among outpatients with hyperkalaemia and Stages 4 and 5 chronic kidney disease (CKD) versus those with Stages 1–3 CKD. MethodsAdults with serum K+ ≥5.1 mmol/L (measured by point-of-care i-STAT device) received SZC 10 g three times daily for 24–72 h until normokalaemia (i-STAT K+ 3.5–5.0 mmol/L) was achieved [correction phase (CP)], followed by once daily SZC 5 g for ≤12 months [maintenance phase (MP)]. Here, patients were stratified by baseline estimated glomerular filtration rate (eGFR <30 or ≥30 mL/min/1.73 m2). Study endpoints included percent achieving normokalaemia during CP and MP, mean serum K+ and bicarbonate during MP, and adverse events (AEs).ResultsOf 751 patients enrolled, 289 (39%), 453 (60%) and 9 (1%) had baseline eGFR values of <30, ≥30 mL/min/1.73 m2 or missing, respectively. During the CP, 82% of patients achieved normokalaemia in both eGFR subgroups within 24 h, and 100 and 95% with baseline eGFR <30 and ≥30 mL/min/1.73 m2, respectively, within 72 h. Corresponding proportions with normokalaemia during the MP were 82 and 90% at Day 365, respectively. Mean serum K+ reduction from baseline during the CP was sustained throughout the MP and serum bicarbonate increased. AEs during the MP were more common in the eGFR <30 ≥30 mL/min/1.73 m2 subgroup.ConclusionsSZC corrects hyperkalaemia and maintains normokalaemia among outpatients regardless of the CKD stage.
      PubDate: Thu, 06 Feb 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfz285
      Issue No: Vol. 36, No. 1 (2020)
       
  • Prescription patterns of dialysate potassium and potassium binders and
           survival on haemodialysis—the French Renal Epidemiology and Information
           Network registry
    • Authors: Mercadal L; Lambert O, Couchoud C, et al.
      Pages: 151 - 159
      Abstract: AbstractBackgroundManagement of potassium disorders in patients on haemodialysis (HD) is complex. We studied prescription patterns of dialysate potassium and potassium binders, and their associations with patient survival.MethodsThis national registry-based study included 25 629 incident adult patients alive after 3 months of HD from 2010 through 2013 and followed-up through 31 December 2014. We used Cox proportional hazard models to estimate multiadjusted mortality hazard ratios (HRs) associated with time-dependent exposure to facility-level dialysate potassium concentrations and patient-level potassium binder exposure.ResultsAlmost all dialysis units used, and generally most often, dialysate potassium concentrations of 2 mmol/L. During this period, use of concentrations <2 mmol/L tended to decrease and those ≥3 mmol/L to increase. In 2014, 9% of units used a single dialysate formula, 41% used two and 50% three or more. The most frequent combinations were 2 and 3 mmol/L (40%), and <2, 2 and 3 mmol/L (37%). Compared with patients on HD in units using only one dialysate formula, those in units using two or three had adjusted mortality HRs of 0.91 [95% confidence interval (CI) 0.82–1.01] and 0.84 (0.75–0.93), respectively. Potassium binders were prescribed for 37% of all patients at baseline. Adjusted mortality HRs associated with doses <4, 4–8 and ≥8 g/day versus none were 1.22 (95% CI 1.04–1.51), 0.6 (0.54–0.66) and 0.25 (0.24–0.33), respectively.ConclusionsDiversity in facility-level use of dialysate potassium concentrations and potassium binder use at an appropriate dose appear to be associated with better survival in HD patients.
      PubDate: Wed, 24 Jun 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa077
      Issue No: Vol. 36, No. 1 (2020)
       
  • The risk of medically uncontrolled secondary hyperparathyroidism depends
           on parathyroid hormone levels at haemodialysis initiation
    • Authors: Tabibzadeh N; Karaboyas A, Robinson B, et al.
      Pages: 160 - 169
      Abstract: AbstractBackgroundOptimal parathyroid hormone (PTH) control during non-dialysis chronic kidney disease (ND-CKD) might decrease the subsequent risk of parathyroid hyperplasia and uncontrolled secondary hyperparathyroidism (SHPT) on dialysis. However, the evidence for recommending PTH targets and therapeutic strategies is weak for ND-CKD. We evaluated the patient characteristics, treatment patterns and PTH control over the first year of haemodialysis (HD) by PTH prior to HD initiation.MethodsWe studied 5683 incident HD patients from 21 countries in Dialysis Outcomes and Practice Patterns Study Phases 4–6 (2009–18). We stratified by PTH measured immediately prior to HD initiation and reported the monthly prescription prevalence of active vitamin D and calcimimetics over the first year of HD and risk of PTH >600 pg/mL after 9–12 months on HD.ResultsThe 16% of patients with PTH >600 pg/mL prior to HD initiation were more likely to be prescribed active vitamin D and calcimimetics during the first year of HD. The prevalence of PTH >600 pg/mL 9–12 months after start of HD was greater for patients who initiated HD with PTH >600 (29%) versus 150–300 (7%) pg/mL (adjusted risk difference: 19%; 95% confidence interval : 15%, 23%). The patients with sustained PTH >600 pg/mL after 9–12 months on HD were younger, more likely to be black, and had higher serum phosphorus and estimated glomerular filtration rates at HD initiation.ConclusionsIncreased PTH before HD start predicted a higher PTH level 9–12 months later, despite greater use of active vitamin D and calcimimetics. More targeted PTH control during ND-CKD may influence outcomes during HD, raising the need for PTH target guidelines in these patients.
      PubDate: Sat, 17 Oct 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa195
      Issue No: Vol. 36, No. 1 (2020)
       
  • Bleeding risk of haemodialysis and peritoneal dialysis patients
    • Authors: van Eck van der Sluijs A; Abrahams A, Rookmaaker M, et al.
      Pages: 170 - 175
      Abstract: AbstractBackgroundDialysis patients have an increased bleeding risk as compared with the general population. However, there is limited information whether bleeding risks are different for patients treated with haemodialysis (HD) or peritoneal dialysis (PD). From a clinical point of view, this information could influence therapy choice. Therefore the aim of this study was to investigate the association between dialysis modality and bleeding risk.MethodsIncident dialysis patients from the Netherlands Cooperative Study on the Adequacy of Dialysis were prospectively followed for major bleeding events over 3 years. Hazard ratios with 95% confidence intervals (CIs) were calculated for HD compared with PD using a time-dependent Cox regression analysis, with updates on dialysis modality.ResultsIn total, 1745 patients started dialysis, of whom 1211 (69.4%) received HD and 534 (30.6%) PD. The bleeding rate was 60.8/1000 person-years for HD patients and 34.6/1000 person-years for PD patients. The time-dependent Cox regression analysis showed that after adjustment for age, sex, primary kidney disease, prior bleeding, cardiovascular disease, antiplatelet drug use, vitamin K antagonist use, erythropoietin use, arterial hypertension, residual glomerular filtratin rate, haemoglobin and albumin levels, bleeding risk for HD patients compared with PD increased 1.5-fold (95% CI 1.0–2.2).ConclusionsIn this large prospective cohort of incident dialysis patients, HD patients had an increased bleeding risk compared with PD patients. In particular, HD patients with a history of prior bleeding had an increased bleeding risk.
      PubDate: Sun, 01 Nov 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa216
      Issue No: Vol. 36, No. 1 (2020)
       
  • Higher mortality risk among kidney transplant recipients than among
           estimated glomerular filtration rate–matched patients with
           CKD—preliminary results
    • Authors: Cheddani L; Liabeuf S, Essig M, et al.
      Pages: 176 - 184
      Abstract: AbstractBackgroundAlthough kidney transplantation prolongs survival relative to dialysis, it is associated with a higher death rate than in the general population. The objective of the present study was to assess and compare the risk of mortality and frequency of non-lethal cardiovascular (CV) events in kidney transplant recipients (KTRs) beyond 1 year after successful transplantation versus patients with chronic kidney disease (CKD) using propensity score–matched analysis of estimated glomerular filtration rate (eGFR) and other parameters.MethodsAfter propensity score matching, we studied 340 KTRs from the French Données Informatisées et Validées en Transplantation cohort and 605 non-transplant patients with CKD (CKDps) from the French Chronic Kidney Disease–Renal Epidemiology and Information Network cohort. The mean ± standard deviation eGFR was 42 ± 13 and 41 ± 12 mL/min/  1.73 m2, respectively (P = 0.649). Descriptive data were completed by a survival analysis with Cox regression models.ResultsAfter a median follow-up period of 2.8 years (KTRs 2.0 years, CKDp 2.9 years), 71 deaths were recorded (31 and 40 in the KTR and CKD groups, respectively). Univariate analysis showed that KTRs had a significantly greater risk of mortality than CKDps. In multivariable analysis, KTRs were found to have a 2.7-fold greater risk of mortality [hazard ratio 2.7 (95% confidence interval 1.6–4.7); P = 0.005]. There was no between-group difference concerning the risk of CV events (P = 0.448). CV death rates in KTRs (29.0%) approximated those of CKDps (22.5%), whereas death rates due to infections were higher in KTRs (19.4% versus 10.0%).ConclusionBeyond 1 year after transplantation, KTRs, who possibly had a longer CKD history, had a significantly greater mortality risk than eGFR-matched CKDps. The excess risk was not associated with CV events.
      PubDate: Thu, 12 Mar 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa026
      Issue No: Vol. 36, No. 1 (2020)
       
  • Acute kidney injury in renal transplant recipients undergoing cardiac
           surgery
    • Authors: Hundemer G; Srivastava A, Jacob K, et al.
      Pages: 185 - 196
      Abstract: AbstractBackgroundAcute kidney injury (AKI) is a key risk factor for chronic kidney disease in the general population, but has not been investigated in detail among renal transplant recipients (RTRs). We investigated the incidence, severity and risk factors for AKI following cardiac surgery among RTRs compared with non-RTRs with otherwise similar clinical characteristics.MethodsWe conducted a retrospective cohort study of RTRs (n = 83) and non-RTRs (n = 83) who underwent cardiac surgery at two major academic medical centers. Non-RTRs were matched 1:1 to RTRs by age, preoperative (preop) estimated glomerular filtration rate and type of cardiac surgery. We defined AKI according to Kidney Disease: Improving Global Outcomes criteria.ResultsRTRs had a higher rate of AKI following cardiac surgery compared with non-RTRs [46% versus 28%; adjusted odds ratio 2.77 (95% confidence interval 1.36–5.64)]. Among RTRs, deceased donor (DD) versus living donor (LD) status, as well as higher versus lower preop calcineurin inhibitor (CNI) trough levels, were associated with higher rates of AKI (57% versus 33% among DD-RTRs versus LD-RTRs; P = 0.047; 73% versus 36% among RTRs with higher versus lower CNI trough levels, P = 0.02). The combination of both risk factors (DD status and higher CNI trough level) had an additive effect (88% AKI incidence among patients with both risk factors versus 25% incidence among RTRs with neither risk factor, P = 0.004).ConclusionsRTRs have a higher risk of AKI following cardiac surgery compared with non-RTRs with otherwise similar characteristics. Among RTRs, DD-RTRs and those with higher preop CNI trough levels are at the highest risk.
      PubDate: Sun, 06 Sep 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa063
      Issue No: Vol. 36, No. 1 (2020)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.239.109.55
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-